<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Oncol</journal-id><journal-id journal-id-type="publisher-id">JO</journal-id><journal-title>Journal of Oncology</journal-title><issn pub-type="ppub">1687-8450</issn><issn pub-type="epub">1687-8469</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19259335</article-id><article-id pub-id-type="pmc">2648643</article-id><article-id pub-id-type="doi">10.1155/2008/931532</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Chemotherapy Administration during Pelvic  Radiation for Cervical Cancer Patients Aged &#x02265;55 Years in  the SEER-Medicare Population</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kunos</surname><given-names>Charles</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Gibbons</surname><given-names>Heidi</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Simpkins</surname><given-names>Fiona</given-names></name><xref ref-type="aff" rid="I2"><sup>2,3</sup></xref><xref ref-type="aff" rid="I3"/></contrib><contrib contrib-type="author"><name><surname>Waggoner</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Radiation Oncology, Case Comprehensive Cancer Center and University Hospitals of Cleveland Case Medical Center, Cleveland, OH 44106, USA</aff><aff id="I2"><sup>2</sup>Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Case Comprehensive Cancer Center and  University Hospitals of Cleveland Case Medical Center, Cleveland, OH 44106, USA</aff><aff id="I3"><sup>3</sup>Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic, Cleveland, OH 44197, USA</aff><author-notes><corresp id="cor1">*Charles Kunos: <email>charles.kunos@uhhospitals.org</email></corresp><fn fn-type="other"><p>Recommended by Charles F. Levenback</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2008</year></pub-date><volume>2008</volume><elocation-id>931532</elocation-id><history><date date-type="received"><day>2</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>31</day><month>7</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Charles Kunos et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>Our study evaluated whether 1999 National Cancer Institute (NCI) chemoradiation guidelines for cervical cancer impacted treatment of women &#x02265;55 years. We identified 385 women &#x02265;55 years (median, 72 years) diagnosed with stage II-IVA cervical cancer between January, 1998 and December, 2002 in the United States Surveillance, Epidemiology, and End Results (SEER)-Medicare registries. Chemoradiation frequency tables were constructed for age, race, community setting, socioeconomic status, and comorbidity index. Of 385 women, 166 (43%) received chemoradiation as primary treatment. Prior to the 1999 NCI clinical alert, 5/43 (12%) in 1998 and 24/54 (44%) in 1999 received chemoradiation. The chemoradiation proportion was 41% (36/87) in 2000, 48% (51/107) in 2001, and 53% (50/94) in 2002 (trend, <italic>P</italic> &#x0003c; .01). Women &#x02265;71 years had significantly lower odds of chemoradiation (<italic>P</italic> = .04). While SEER-Medicare data indicated an increasing trend for chemoradiation after the 1999 NCI clinical alert, chemoradiation was less frequent in elderly women with cervical cancer.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. Introduction</title><p>Cervical cancer is the second most frequentlydiagnosed cancer among women worldwide, with nearly 80 percent arising amongwomen in developing countries [<xref ref-type="bibr" rid="B1">1</xref>]. Despite effectivescreening modalities, nearly 40 percent of women in the United States presentwith locally advanced stageII-IVA cervical cancers extending beyond the cervix to invadevaginal or parametrial, pelvic sidewall, bladder, or rectal tissues [<xref ref-type="bibr" rid="B1">1</xref>].</p><p>In women with locally advanced cervical cancer, threerandomized trials have shown concurrent pelvic radiation and platinum-basedchemotherapy meaningfully contribute to improved disease-free survival [<xref ref-type="bibr" rid="B2">2</xref>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>]. These compellingclinical results prompted the NationalCancer Institute (NCI) to issue a publicized national clinical alert in February,1999 advising concurrentplatinum-based chemotherapy and radiation for women with locally advanced cervicalcancer [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>According to the United States Surveillance,Epidemiology, and End-Results (SEER) cancer registries between January, 1998and December, 2002, 35 percent of annual incident cervical cancer patientsarose in women aged 55 years or older (&#x02265;55). However, women &#x02265;55 years accounted for 55 percent of cervical cancer-relatedmortality during this time period. Widening disparity between cervical cancerincidence and mortality among women &#x02265;55 years questions whether chemoradiationhas been implemented as a national practice pattern in this patient population. Population-based studies are needed to evaluate the national impact of the 1999NCI clinical alert advising chemoradiation for locally advanced cervical cancer. The merged SEER-Medicare datasetoffers a population-based cohort of women &#x02265;55 years longitudinally tracked over the course ofcancer diagnosis, treatment, and follow-up [<xref ref-type="bibr" rid="B6">6</xref>]. The utility of SEER-Medicare data to identify chemotherapy administrationhas been validated [<xref ref-type="bibr" rid="B7">7</xref>]. This study determines the frequency of chemoradiation administration in women &#x02265;55 years diagnosed with cervical cancer immediately before and afterthe 1999 NCI clinical alert using the population-based SEER-Medicare dataset. Secondary aims included identifyingfactors in women aged &#x02265;55 yearsassociated with decreased chemotherapy administration during radiation.</p></sec><sec sec-type="section" id="sec2"><title>2. Methods</title><sec id="sec2.1"><title>2.1. Data Source</title><p>Data were abstracted from the NCI-sponsored SEER-Medicareprogram using the SEER 11-registries plus Alaska 1998&#x02013;2003 dataset (July, 2006edition, [<xref ref-type="bibr" rid="B8">8</xref>]). Because SEER data contain nounique personal identifiers and thus are available for public use and research,approval by an ethics committee or informed consent is not necessary to performour analyses. In general, SEER data cover26 percent of the US population, and therefore, are considered representativeof the whole US population [<xref ref-type="bibr" rid="B8">8</xref>]. The SEER programregistries routinely collect data on patient demographics (i.e.,age, race [Caucasian, African-American, Asian, Hispanic, or other], patientresidence, and socioeconomic status [income per census tract]), primary tumorsite (i.e., cervix), tumor morphology and stage at diagnosis, first course oftreatment, and follow-up for vital status. The SEER program does not recordchemotherapy administration.</p><p>To identify claims for chemotherapy administration [<xref ref-type="bibr" rid="B7">7</xref>], data were abstracted from three mergedSEER-Medicare files: Medicare provider analysis and review (MEDPAR), carrier claims(NCH), and outpatient claims (OUTSAF). MEDPAR files record all calendar year partA short stay, long stay, and skilled nursing facility claims. NCH files containcalendar year Center for Medicare and MedicaidServices (CMS) physician/supplier part B claims. OUTSAF files list calendaryear claims for hospital outpatient departments, rural health clinics, renaldialysis facilities, outpatient rehabilitation facilities, comprehensiveoutpatient rehabilitation facilities, and community mental health centers [<xref ref-type="bibr" rid="B9">9</xref>]. Procedurecodes for chemotherapy administration made within 3 months after diagnosis ofcervical cancer were ascertained [<xref ref-type="bibr" rid="B10">10</xref>].</p></sec><sec id="sec2.2"><title>2.2. Study Population</title><p>The study population consisted of all femalepatients, without previous or synchronous invasive cancers, who were diagnosedwith stage II, III, or IVA cervical cancer between 1998 and 2002 (<italic>n</italic> = 3, 601). StageI patients (<italic>n</italic> = 1, 363) were excluded because they are not reliably substaged(i.e., IB1 or IB2) in the SEER-Medicare database and the majority underwentdefinitive surgery (1,044 of 1,363 [76.6%]). Women with unknown stage (<italic>n</italic> = 357), stage0 (<italic>n</italic> = 47), and stage IVB(<italic>n</italic> = 402) cervical cancers were excluded. To ensure that chemotherapy claimscoincided with radiation and are not missed secondary to payment by privateinsurance (<italic>n</italic> = 431), included women must have had Medicare parts A and B coveragefor the duration of their cancer care (<italic>n</italic> = 1, 001) [<xref ref-type="bibr" rid="B7">7</xref>]. For determination of chemoradiation administration, includedwomen &#x02265;55 years must have undergone radiation (external pelvic and brachytherapyimplant) for primary treatment of their cervical cancer (<italic>n</italic> = 385).</p></sec><sec id="sec2.3"><title>2.3. Comorbidity Index</title><p>The Charlson comorbidity index is a summarymeasure of 19 comorbid conditions, each assigned a weighting factor accordingto its potential for influencing mortality [<xref ref-type="bibr" rid="B11">11</xref>]. Charlson comorbidity indices [<xref ref-type="bibr" rid="B11">11</xref>] were calculated by abstracting Medicare ICD-9-CM diagnosisand procedure codes relating to cardiovascular, cerebrovascular, hepatic,renal, diabetic, connective tissue, or neoplastic disease among inpatient andoutpatient claims made for each woman one year prior to the diagnosis ofcervical cancer [<xref ref-type="bibr" rid="B12">12</xref>&#x02013;<xref ref-type="bibr" rid="B14">14</xref>]. Women diagnosed with chronic end-stage renal disease orlisted in the SEER-Medicare dataset as having diagnosis codes for renaldisease, renal failure, or renal insufficiency were considered women as having renaldisease comorbidity [<xref ref-type="bibr" rid="B10">10</xref>].</p></sec><sec id="sec2.4"><title>2.4. Statistical Analysis</title><p>For this analysis, the day of diagnosis in SEER wasarbitrarily assigned as the 15th of the month. Women were considered to havereceived concurrent chemoradiation therapy if there was at least one submittedbilling claim for chemotherapy within a three-month period after diagnosis andradiation treatment. Chi-square tests for categorical variables and Student's <italic>t</italic>-tests for continuous variables wereused to compare differences in demographic and tumor variables by chemoradiationadministration. Adjusted odds ratios for chemoradiation were generated using multivariatelogistic regression models sequentially controlling age, race, residence,socioeconomic status, comorbidity, tumor stage, and histology as defined in<xref ref-type="table" rid="tab1">Table 1</xref>. A <italic>P</italic>-value <italic>&#x003b1;</italic> &#x0003c; 0.05(two-sided) was used to determine statistical significance. Computer programingand statistical analyses were performed using SAS software version 9.1 (SASInstitute, Cary, NC).</p></sec></sec><sec sec-type="section" id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Patient Demographics</title><p>After exclusions, 385 women aged &#x02265;55 yearsunderwent pelvic radiation and intracavitary brachytherapy for primarytreatment of cervical cancer between January, 1998 and December, 2002. Medianage was 72 years (range 55&#x02013;94 years). <xref ref-type="table" rid="tab1">Table 1</xref> presents patient demographic and tumorvariables for the 385 women included in this analysis. The majority of caseswere stage II squamous cell cancers diagnosed in Caucasian women who had minimal comorbiditiesand who resided in large metropolitan areas.</p></sec><sec id="sec3.2"><title>3.2. Concurrent Chemoradiation</title><p>Among women aged &#x02265;55 years identified in the SEER-Medicare dataset, 166 of 385(43%) received chemoradiation. Cisplatin chemotherapy was specifically claimedin 129 of 166 (78%) women. Before the 1999 NCI clinical alert, 30 percent ofwomen aged &#x02265;55 years (29 of 97 women) identified in the SEER-Medicare registry received at least onechemotherapy dose during radiation (see <xref ref-type="table" rid="tab2">Table 2</xref>). In the year 2000 and afterthe 1999 NCI clinical alert, the proportion receiving chemoradiation was 41percent of women aged &#x02265;55 years (36 of 87 women). Afterwards, theproportion receiving chemoradiation was greater than 50 percent (see <xref ref-type="table" rid="tab2">Table 2</xref>). Between 1998 and 2002, a significant increasing trend for chemoradiation administrationwas observed among women aged &#x02265;55 years registered in the SEER-Medicare dataset (<italic>P</italic> &#x0003c; .01). Themedian number of chemotherapy claims during radiation was four (mean 4.2,standard deviation 1.9, <xref ref-type="table" rid="tab2">Table 2</xref>). Among women treated with chemoradiation, 78of 166 (47%) received five or more cycles of chemotherapy.<xref ref-type="table" rid="tab3"> Table 3</xref> compares variablesin univariate analyses evaluating patients who received concurrent chemotherapyand radiation compared to those who received radiation alone. The mean age ofwomen receiving chemoradiation was significantly younger (<xref ref-type="table" rid="tab3">Table 3</xref>, <italic>P</italic> &#x0003c; .001). The proportion of women residingin urban, less urban, and rural areas receiving chemoradiation wassignificantly higher than receiving radiation alone (20% <italic>versus</italic> 10%, <italic>P</italic> = .03). Chemotherapyuse during radiation was not associated with race, socioeconomicstatus, tumor histology or stage, or comorbidity index. The proportion of womendiagnosed with renal disease comorbidity was similar among chemoradiation (18/166, 11%)and radiation alone (21/219, 10%) treatment groups (<italic>P</italic> = .73).</p><p>					<xref ref-type="table" rid="tab4">Table 4</xref> presents multivariate analyses for oddsof receiving concurrent chemoradiation adjusting for patient demographic and tumordifferences. Women aged 71 years or older had a significantly decreased odds ofundergoing chemoradiation treatment as compared to women aged 55 to 70 years (<italic>P</italic> = .04). For women 71 years or older, the proportion of women with renal disease whoreceived chemoradiation (9 of 95, 10%) and radiation alone (7 of 138, 5%) wassimilar (<italic>P</italic> = .19). In multivariate analyses, women residingin urban, less urban, and rural areas had significantly increased odds ofundergoing chemoradiation treatment as compared to women residing inmetropolitan areas (<italic>P</italic> &#x0003c; .001). Theproportion of women 71 years or older in big metropolitan, metropolitan, andurban/less urban/rural areas was 42 percent (99 of 235), 35 percent (33 of 61),and 36 percent (20 of 56), respectively (<italic>P</italic> = .41). Race,socioeconomic status, comorbidity index, and tumor histology or stage were notsignificant confounders for chemoradiation treatment.</p></sec></sec><sec sec-type="section" id="sec4"><title>4. Discussion</title><p>The present data from the US population-based SEER-Medicare database indicate that the 1999 NCI clinicalalert for platinum-based chemoradiation has had an impact on chemoradiation usefor locally advanced stageII-IVA cervical cancers diagnosed in women &#x02265;55 years. Eighteenmonths before the NCI clinical alert, less than 30 percent of women &#x02265;55years received chemoradiation. However, within 18 months of the NCI clinical alert, the proportion of women &#x02265;55years with locally advanced cervical cancer receiving chemoradiationsignificantly rose to 50 percent. Since chemoradiation use has steadily risenthrough the last SEER-Medicare cohort available for study (i.e., 2002), therecommendation has been followed but a substantial fraction of women &#x02265;55 yearsstill did not receive concurrent chemoradiation in 2002 three years after theNCI clinical alert.</p><p>Age is a risk factor for pelvic and distant relapse aswell as death after treatment for cervical cancer. In multivariate analysesconducted by the Gynecologic Oncology Group evaluating radiation and chemotherapeuticradiation sensitizers [<xref ref-type="bibr" rid="B15">15</xref>], older patient age at diagnosis significantlyconferred less cervical cancer recurrence or death. These findings led to thecontroversial suggestion that younger patient age at diagnosis was associatedwith high mortality; and yet, the inferior mortality outcomes attributable toyounger patient age have vanished in the era of platinum-based chemoradiationas no contemporary Gynecologic Oncology Group or cooperative group studyidentifies age as a significant confounder upon survival outcomes [<xref ref-type="bibr" rid="B2">2</xref>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>]. While platinum-based chemoradiation appears to havedecreased mortality in younger women, it remains unknown whether older womenare deriving full survival benefit from chemoradiation treatment. Perceived andactual hematological, renal, gastrointestinal, and neural toxicities of platinumchemotherapy perhaps influence physicians to not consider coadministration ofchemotherapy during radiation in older women. These data indicate thatsignificantly fewer women older than 71 years who have locally advancedcervical cancer receive chemoradiation&#x02014;even though thesurvival of these older patients who receive chemoradiation approaches that ofyounger patients who undergo chemoradiation treatment [<xref ref-type="bibr" rid="B2">2</xref>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B16">16</xref>]. This study is not the first to identify this age trend.</p><p>In a pattern of care study [<xref ref-type="bibr" rid="B17">17</xref>], it was reported that 63 percent of all women captured in this survey underwent concurrent chemotherapy and radiation in 1999, ascompared to 26 percent in 1998. Twenty-five percent of women 60 years or olderreceived chemoradiation as compared to 48 percent among women aged 40 years orless (<italic>P</italic> = .02) [<xref ref-type="bibr" rid="B17">17</xref>]. In an earlier analysis of the SEER-Medicare databasecontrolling for racial and socioeconomic factors, increasing age was stronglyassociated (<italic>P</italic> &#x0003c; .0001) withreceiving neither chemoradiation nor radiation treatment for cervical cancer [<xref ref-type="bibr" rid="B18">18</xref>]. However, both studies capture only those women treatedthrough 1999, study periods ending when the 1999 NCI clinical alert were released. Thus, a true assessment of theimpact of the NCI clinical alert is essentially unknown.</p><p>The present data are thefirst assessment of chemoradiation treatment after the 1999 NCI clinical alert forchemoradiation treatment of locally advanced cervical cancer in women aged &#x02265;55 years. The US SEER-Medicare dataset is an NCI-sponsored cancer registry that reflectsa wide range of race/ethnic, demographic, and socioeconomic diversity and thatavails itself to cancer health service delivery analyses in women aged &#x02265;55years. The data presented herein reflectprospectively collected but not randomized practice and usage ofchemoradiation. These data measure the impact of randomized clinical trials incervical cancer, as popularized by the national 1999 NCI clinical alert, onclinical chemoradiation practices for the treatment of cervical cancer. Thus, thesedata conveniently sample a small proportion of the total number of women withlocally advanced cervical cancer treated in the US  each year. Consequently, analyseson these nonrandomly treated women can only be considered as an interpretiveguide for changing trends in chemoradiation usage for locally advanced cervicalcancer. Indeed, the present data suggest that women &#x02265;55 years with locally advanced cervical cancer areincreasingly likely to receive chemoradiation. Data also suggest thatchemoradiation use has significantly lagged behind in women 71 years orolder compared to women 55 to 70 years. Perhaps physicians applied the NCI recommendations tosome groups of women more consistently than others.</p><p>In this study of theSEER-Medicare population, age emerges as an important factor influencingwhether patients receive chemoradiation. While the NCI clinical alert hasstrongly endorsed use of chemoradiation for all patients with locally advancedcervical cancer, it is worth considering the causes of disparity inchemoradiation use among younger and older women. The exact regimen ofchemotherapy administration, patient-specific chemotherapy dosage, and adverseeffects of treatment cannot be abstracted reliably from the SEER-Medicaredatabase. While reluctance of older patients to receive chemotherapy due toperceived toxicities, tolerability, or an apathetic attitude often aredifficult to enumerate, physical limitations such as comorbid disease may bemore reliably estimated in a population-based database that records thesefactors. In the current study, a high Charlson comorbidity index was notassociated with more infrequent chemoradiation treatment. Comorbid renaldisease, as identified by diagnosis codes for renal disease, renal failure, orrenal insufficiency, also was not associated with infrequent chemoradiationtreatment.</p><p>Demographic variables ofrace, socioeconomic status, and tumor variables of histology and clinical stagewere not associated with more infrequent chemoradiation treatment, a reassuringfinding of this study. However, a significant disparity in the proportion ofwomen &#x02265;55 years in metropolitan and nonmetropolitan residencies was observedin this study. Only 40 percent of the women residing in metropolitan areas ascompared to 60 percent of women residing in urban, less urban, and rural residenciesreceived chemoradiation during the entire 1998 to 2002 period under study (<italic>P</italic> = .03). Disparity in age cohorts amongresidences does not account for this difference as the proportion of women aged71 years or older among big metropolitan, metropolitan, and urban/lessurban/rural areas is similar (<italic>P</italic> = .41). The issues surrounding the more frequent use of radiation alone in metropolitanresidencies are difficult to abstract but perhaps are related to unreportedcomorbid disease, patient refusal, and perceived toxicities/tolerability of thecombined treatment regimen. The data cannot exclude the possibility thathealthcare-system-related factors, such as access to care or differences inreferrals for chemotherapy consultation, could explain the findings of thecurrent study. The reasons why older women do not receive chemotherapy remainelusive, and perhaps, future population-based studies may provide moremeaningful insight.</p><p>Our study is not withoutinterpretative criticism. The populationcovered by SEER program representing 26 percent of the general population comparesfavorably to US census population data with regard to measures of poverty andeducation, but has a higherproportion of urban and foreign-born persons in the registry as comparedto the general US population. Census population estimates for the year 2000 [<xref ref-type="bibr" rid="B19">19</xref>] suggest that 73 percent of women aged &#x02265;55 years live in metropolitan areas as compared to85 percent registered in the SEER-Medicare dataset. There may also bedifferences in the underlying racial distribution of the SEER-Medicare datasetcompared to the US population comprising new incident cases of cervical cancer [<xref ref-type="bibr" rid="B20">20</xref>]. ThisSEER-Medicare dataset used to analyze the impact of the NCI clinical alert is limited to women aged &#x02265;55 years that must have been enrolled in MedicarePart A and B coverage for the duration of their cervical cancer treatment. Thus,by limiting the dataset by an age criterion of &#x02265;55 years, this analysis does not capturechemoradiation treatment in young women who comprise the majority of new incident cases inthe US. Moreover, identification of chemoradiation in the SEER-Medicare populationfollows the Centers for Medicare and Medicaid Services' coverage policiesrelating to chemotherapy administration. Current Centers for Medicare andMedicaid Services policy permits fee-for-service reimbursement for intravenouschemotherapy [<xref ref-type="bibr" rid="B7">7</xref>], including cisplatin chemotherapy administration. AsMedicare billing claims for chemotherapy administration are often coded withinsix months of initial cancer diagnosis [<xref ref-type="bibr" rid="B7">7</xref>], this analysis' three-monthtimeframe for coincident chemotherapy and radiation treatment in theSEER-Medicare dataset is reasonable. Women simultaneously enrolled by a privateinsurer were excluded as chemotherapy administration may have been paid by thisentity rather than Medicare, and thus falsely skewing results toward treatmentwith radiation alone. Another limitation is that comorbid disease documentationin a population-based dataset is derived from claims-based administrative coding,which may generally be less complete than data obtained from direct medicalchart review. Interpretative criticism also concerns the timeliness of theSEER-Medicare cohort under study, as these patients may be poorly reflective ofmodern chemoradiation practice; and yet, SEER data and Medicare data areinfrequently merged. As such, the 1998&#x02013;2002 SEER-Medicarepatient population represents the most contemporary cohort in which to studyconcurrent SEER radiation and Medicare chemotherapy recorded administration.</p><p>The current analysis of 1998&#x02013;2002 SEER-Medicaredata indicates increased utilization of chemoradiation treatment since the 1999NCI clinical alert stronglyadvocating for concurrent chemotherapy and radiation for locally advancedcervical cancer. Older age has been considered a barrier to chemotherapy. Between1998 and 2002, the population-based SEER-Medicare registry identifies 43percent of the women &#x02265;55 years with locally advanced cervicalcancer receiving chemoradiation despite published guidelines to the contrary. Whileour study is provocative, it is unable to definitively assess current nationalchemoradiation practice patterns. To further corroborate our findings, it wouldbe interesting to analyze NCI-sponsoredclinical trials enrolling women aged &#x02265;55 years to determine if the number of chemotherapy cyclesgiven during radiation impacts clinical outcome. Further analysis of nationalpractice patterns from future US Surveillance, Epidemiology, and End-Results-Medicaremergers is warranted to identify contributing factors leading to the disparityin incidence and mortality among women &#x02265;55 years with locally advanced cervicalcancer.</p></sec></body><back><ack><title>Acknowledgment</title><p>This paper is supported in part by Grant no. (K12 CA076917) to Charles Kunos from the National Institutes of Health and the CASE Comprehensive Cancer Center.</p></ack><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waggoner</surname><given-names>SE</given-names></name></person-group><article-title>Cervical cancer</article-title><source><italic>The Lancet</italic></source><year>2003</year><volume>361</volume><issue>9376</issue><fpage>2217</fpage><lpage>2225</lpage></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitney</surname><given-names>CW</given-names></name><name><surname>Sause</surname><given-names>W</given-names></name><name><surname>Bundy</surname><given-names>BN</given-names></name><etal/></person-group><article-title>Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and southwest Oncology Group study</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>1999</year><volume>17</volume><issue>5</issue><fpage>1339</fpage><lpage>1348</lpage><pub-id pub-id-type="pmid">10334517</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>PG</given-names></name><name><surname>Bundy</surname><given-names>BN</given-names></name><name><surname>Watkins</surname><given-names>EB</given-names></name><etal/></person-group><article-title>Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer</article-title><source><italic>The New England Journal of Medicine</italic></source><year>1999</year><volume>340</volume><issue>15</issue><fpage>1144</fpage><lpage>1153</lpage><pub-id pub-id-type="pmid">10202165</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eifel</surname><given-names>PJ</given-names></name><name><surname>Winter</surname><given-names>K</given-names></name><name><surname>Morris</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01</article-title><source><italic>Journal of Clinical Oncology</italic></source><year>2004</year><volume>22</volume><issue>5</issue><fpage>872</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">14990643</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McNeil</surname><given-names>C</given-names></name></person-group><article-title>New standard of care for cervical cancer sets stage for next questions</article-title><source><italic>Journal of the National Cancer Institute</italic></source><year>1999</year><volume>91</volume><issue>6</issue><fpage>500</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">10088618</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>J</given-names></name><name><surname>Klabunde</surname><given-names>C</given-names></name><name><surname>Schrag</surname><given-names>D</given-names></name><name><surname>Bach</surname><given-names>P</given-names></name><name><surname>Riley</surname><given-names>G</given-names></name></person-group><article-title>Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population</article-title><source><italic>Medical Care</italic></source><year>2002</year><volume>40</volume><issue>supplement 8</issue><fpage>IV3</fpage><lpage>IV18</lpage></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>JL</given-names></name><name><surname>Harlan</surname><given-names>LC</given-names></name><name><surname>Fahey</surname><given-names>A</given-names></name><etal/></person-group><article-title>Utility of the SEER-Medicare Data to identify chemotherapy use</article-title><source><italic>Medical Care</italic></source><year>2002</year><volume>40</volume><issue>supplement 8</issue><fpage>IV55</fpage><lpage>IV61</lpage></citation></ref><ref id="B8"><label>8</label><citation citation-type="other">National Cancer Institute, Cancer Statistics Branch, United States Surveillance, Epidemiology, and End Results (SEER) Public-Use Data (1973&#x02013;1999), Vol. 2007, 2007</citation></ref><ref id="B9"><label>9</label><citation citation-type="other">National Cancer Institute, Cancer Statistics Branch, United States Surveillance, Epidemiology, and End Results (SEER) Medicare Linked Database (1973&#x02013;2002), Vol. 2007, 2007</citation></ref><ref id="B10"><label>10</label><citation citation-type="other">Centers for Medicare and Medicaid Services and United States Department of Health and Human Services Healthcare Common Procedure Coding System, 2007</citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Charlson</surname><given-names>M</given-names></name><name><surname>Pompei</surname><given-names>P</given-names></name><name><surname>Ales</surname><given-names>K</given-names></name><name><surname>MacKenzie</surname><given-names>CR</given-names></name></person-group><article-title>A new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title><source><italic>Journal of Chronic Diseases</italic></source><year>1987</year><volume>40</volume><issue>5</issue><fpage>373</fpage><lpage>383</lpage><pub-id pub-id-type="pmid">3558716</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klabunde</surname><given-names>C</given-names></name><name><surname>Potosky</surname><given-names>A</given-names></name><name><surname>Legler</surname><given-names>J</given-names></name><name><surname>Warren</surname><given-names>J</given-names></name></person-group><article-title>Development of a comorbidity index using physician claims data</article-title><source><italic>Journal of Clinical Epidemiology</italic></source><year>2000</year><volume>53</volume><issue>12</issue><fpage>1258</fpage><lpage>1267</lpage><pub-id pub-id-type="pmid">11146273</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="other">National Cancer Institute, Cancer Statistics Branch, United States Surveillance, Epidemiology, and End Results (SEER) Medicare Linked Database (1973&#x02013;2002), Calculation of comorbidity weights, Vol. 2007, 2007</citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klabunde</surname><given-names>C</given-names></name><name><surname>Warren</surname><given-names>J</given-names></name><name><surname>Legler</surname><given-names>J</given-names></name></person-group><article-title>Assessing comorbidity using claims data: an overview</article-title><source><italic>Medical Care</italic></source><year>2002</year><volume>40</volume><issue>supplement 8</issue><fpage>26</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">11748424</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stehman</surname><given-names>FB</given-names></name><name><surname>Bundy</surname><given-names>BN</given-names></name><name><surname>DiSaia</surname><given-names>PJ</given-names></name><name><surname>Keys</surname><given-names>HM</given-names></name><name><surname>Larson</surname><given-names>JE</given-names></name><name><surname>Fowler</surname><given-names>WC</given-names></name></person-group><article-title>Carcinoma of the cervix treated with radiation therapy&#x02014;I: a multi-variate analysis of prognostic variables in the gynecologic oncology Group</article-title><source><italic>Cancer</italic></source><year>1991</year><volume>67</volume><issue>11</issue><fpage>2776</fpage><lpage>2785</lpage><pub-id pub-id-type="pmid">2025841</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Gibb</surname><given-names>R</given-names></name><name><surname>Geevarghese</surname><given-names>S</given-names></name><etal/></person-group><article-title>Cervical carcinoma in the elderly. An analysis of patterns of care and outcome</article-title><source><italic>Cancer</italic></source><year>2005</year><volume>103</volume><issue>1</issue><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">15540239</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eifel</surname><given-names>PJ</given-names></name><name><surname>Moughan</surname><given-names>J</given-names></name><name><surname>Erickson</surname><given-names>B</given-names></name><name><surname>Iarocci</surname><given-names>T</given-names></name><name><surname>Grant</surname><given-names>D</given-names></name><name><surname>Owen</surname><given-names>J</given-names></name></person-group><article-title>Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study</article-title><source><italic>International Journal of Radiation Oncology, Biology, Physics</italic></source><year>2004</year><volume>60</volume><issue>4</issue><fpage>1144</fpage><lpage>1153</lpage></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coker</surname><given-names>A</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Eggleston</surname><given-names>K</given-names></name></person-group><article-title>Socioeconomic status and cervical cancer survival among older women: findings from the SEER-Medicare linked data cohorts</article-title><source><italic>Gynecologic Oncology</italic></source><year>2006</year><volume>102</volume><issue>2</issue><fpage>278</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">16434087</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="other">United States Census Bureau, United States Census 2000 Demographic Profiles, Vol. 2008, 2008</citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>DA</given-names></name><name><surname>Barnholtz-Sloan</surname><given-names>JA</given-names></name><name><surname>Patel</surname><given-names>MK</given-names></name><name><surname>Malone</surname><given-names>JM</given-names></name><name><surname>Chuba</surname><given-names>PJ</given-names></name><name><surname>Schwartz</surname><given-names>K</given-names></name></person-group><article-title>A population-based study of racial and thnic differences in survival among women with invasive cervical cancer: analysis of Surveillance, Epidemiology, and End Results data</article-title><source><italic>Gynecologic Oncology</italic></source><year>2005</year><volume>97</volume><issue>2</issue><fpage>550</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">15863159</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Patient demographics (<italic>n</italic> = 385).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Age*</th><th align="center" rowspan="1" colspan="1">73.3 &#x000b1; 0.37 (55&#x02013;94 years)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Stage</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">213 (55.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">163 (42.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">IVA</td><td align="center" rowspan="1" colspan="1">9 (2.3%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Year of diagnosis</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1998</td><td align="center" rowspan="1" colspan="1">43 (11.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">1999</td><td align="center" rowspan="1" colspan="1">54 (14.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">2000</td><td align="center" rowspan="1" colspan="1">87 (22.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">2001</td><td align="center" rowspan="1" colspan="1">107 (27.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">2002</td><td align="center" rowspan="1" colspan="1">94 (24.4%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Histology</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Squamous</td><td align="center" rowspan="1" colspan="1">289 (75.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">55 (14.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Adenosquamous</td><td align="center" rowspan="1" colspan="1">13 (3.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">28 (7.3%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="center" rowspan="1" colspan="1">237 (61.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">African-American</td><td align="center" rowspan="1" colspan="1">74 (19.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Asian</td><td align="center" rowspan="1" colspan="1">34 (8.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hispanic</td><td align="center" rowspan="1" colspan="1">25 (6.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">15 (3.9%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Location</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Big metropolitan (&#x02265;250,000)</td><td align="center" rowspan="1" colspan="1">235 (61.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Metropolitan (20,000 to 249,999)</td><td align="center" rowspan="1" colspan="1">94 (24.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Urban (2,500&#x02013;19,999, adjacent metropolitan area)</td><td align="center" rowspan="1" colspan="1">17 (4.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Less urban (2,500&#x02013;19,999, not adjacent metro area)</td><td align="center" rowspan="1" colspan="1">32 (8.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rural (&#x0003c;2,500)</td><td align="center" rowspan="1" colspan="1">7 (1.8%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Socioeconomic status (median income per census tract)*</td><td align="center" rowspan="1" colspan="1">							$44,540  &#x000b1;$1,125</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity index, Charlson</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">274 (71.2%)</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">63 (16.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">28 (7.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">3+</td><td align="center" rowspan="1" colspan="1">20 (5.2%)</td></tr></tbody></table><table-wrap-foot><fn><p>*Mean &#x000b1;Standard Error of Mean.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Concurrent chemoradiation by year of treatment and by number of claims(cycles) within &#x000b1;3 months of radiation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Year*</th><th align="center" rowspan="1" colspan="1"># Chemoradiation/Total # Women</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1998</td><td align="center" rowspan="1" colspan="1">5/43 (11.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">1999</td><td align="center" rowspan="1" colspan="1">24/54 (44.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">2000</td><td align="center" rowspan="1" colspan="1">36/87 (41.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">2001</td><td align="center" rowspan="1" colspan="1">51/107 (47.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">2002</td><td align="center" rowspan="1" colspan="1">50/94 (53.2%)</td></tr><tr><td align="center" colspan="2" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Cycles</td><td align="center" rowspan="1" colspan="1">Total # Women</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">2 to 4</td><td align="center" rowspan="1" colspan="1">68</td></tr><tr><td align="left" rowspan="1" colspan="1">5 to 6</td><td align="center" rowspan="1" colspan="1">69</td></tr><tr><td align="left" rowspan="1" colspan="1">7 or more</td><td align="center" rowspan="1" colspan="1">9</td></tr></tbody></table><table-wrap-foot><fn><p>*MH Chi-square = 15.83; <italic>P</italic> &#x0003c; .001 for trend.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Univariate comparison of patients who received chemoradiation treatment versus those who received radiation treatment alone.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Chemoradiation (<italic>n</italic> = 166)</th><th align="center" rowspan="1" colspan="1">RT alone (<italic>n</italic> = 219)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value*</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">71.7 &#x000b1; 0.48</td><td align="center" rowspan="1" colspan="1">74.4 &#x000b1; 0.53</td><td align="center" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Stage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.393</td></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">89 (53.6%)</td><td align="center" rowspan="1" colspan="1">124 (56.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">74 (44.6%)</td><td align="center" rowspan="1" colspan="1">89 (40.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">IVA</td><td align="center" rowspan="1" colspan="1">3 (1.8%)</td><td align="center" rowspan="1" colspan="1">6 (2.7%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Histology</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.628</td></tr><tr><td align="left" rowspan="1" colspan="1">Squamous</td><td align="center" rowspan="1" colspan="1">129 (77.7%)</td><td align="center" rowspan="1" colspan="1">160 (73.1%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">23 (13.8%)</td><td align="center" rowspan="1" colspan="1">32 (14.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Adenosquamous</td><td align="center" rowspan="1" colspan="1">4 (2.4%)</td><td align="center" rowspan="1" colspan="1">9 (4.1%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">10 (6.0%)</td><td align="center" rowspan="1" colspan="1">18 (8.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.445</td></tr><tr><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="center" rowspan="1" colspan="1">97 (58.4%)</td><td align="center" rowspan="1" colspan="1">140 (63.9%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">African-American</td><td align="center" rowspan="1" colspan="1">34 (20.5%)</td><td align="center" rowspan="1" colspan="1">40 (18.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hispanic</td><td align="center" rowspan="1" colspan="1">6 (3.6%)</td><td align="center" rowspan="1" colspan="1">9 (4.1%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Asian</td><td align="center" rowspan="1" colspan="1">14 (8.4%)</td><td align="center" rowspan="1" colspan="1">20 (9.1%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">15 (9.0%)</td><td align="center" rowspan="1" colspan="1">10 (4.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Location</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.028</td></tr><tr><td align="left" rowspan="1" colspan="1">Big metropolitan (&#x02265;250,000)</td><td align="center" rowspan="1" colspan="1">88 (53.0%)</td><td align="center" rowspan="1" colspan="1">147 (67.1%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Metropolitan (20,000  to 249,999)</td><td align="center" rowspan="1" colspan="1">44 (26.5%)</td><td align="center" rowspan="1" colspan="1">50 (22.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Urban (2,500&#x02013;19,999, adjacent metro area)</td><td align="center" rowspan="1" colspan="1">11 (6.6%)</td><td align="center" rowspan="1" colspan="1">6 (2.7%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Less urban (2,500&#x02013;19,999, not adjacent metro area)</td><td align="center" rowspan="1" colspan="1">19 (11.4%)</td><td align="center" rowspan="1" colspan="1">13 (5.9%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Rural (&#x0003c;2,500)</td><td align="center" rowspan="1" colspan="1">4 (2.4%)</td><td align="center" rowspan="1" colspan="1">3 (1.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Socioeconomic status (median income per census tract)</td><td align="center" rowspan="1" colspan="1">$44,308  &#x000b1;$1,512</td><td align="center" rowspan="1" colspan="1">$44,715  &#x000b1;$1,614</td><td align="center" rowspan="1" colspan="1">.858</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity index, Charlson</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">.641</td></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">116 (69.9%)</td><td align="center" rowspan="1" colspan="1">158 (72.1%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">31 (18.7%)</td><td align="center" rowspan="1" colspan="1">32 (14.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">10 (6.0%)</td><td align="center" rowspan="1" colspan="1">18 (8.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">3+</td><td align="center" rowspan="1" colspan="1">9 (5.4%)</td><td align="center" rowspan="1" colspan="1">11 (5.0%)</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>*Student's <italic>t</italic>-test or chi-square for frequency data.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" position="float"><label>Table 4</label><caption><p>Multivariate analysis for chemoradiation administration within 3 months after diagnosis in women with stages II-IVA cervical cancer from 1998 to 2002.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Patient  and tumor characteristics</th><th align="center" rowspan="1" colspan="1">number of cases (<italic>n</italic> = 385)</th><th align="center" rowspan="1" colspan="1">Odds  ratio* of chemoradiation</th><th align="center" rowspan="1" colspan="1">95% Confidence interval</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">55&#x02013;70 years</td><td align="center" rowspan="1" colspan="1">152 (39.5%)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;71 years</td><td align="center" rowspan="1" colspan="1">233 (60.5%)</td><td align="center" rowspan="1" colspan="1">0.62</td><td align="center" rowspan="1" colspan="1">0.42&#x02013;0.94</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Stage</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">213 (55.3%)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">163 (42.3%)</td><td align="center" rowspan="1" colspan="1">0.96</td><td align="center" rowspan="1" colspan="1">0.63&#x02013;1.47</td></tr><tr><td align="left" rowspan="1" colspan="1">IVA</td><td align="center" rowspan="1" colspan="1">9 (2.3%)</td><td align="center" rowspan="1" colspan="1">0.59</td><td align="center" rowspan="1" colspan="1">0.14&#x02013;2.50</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Histology</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Squamous</td><td align="center" rowspan="1" colspan="1">289 (75.1%)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Adenocarcinoma</td><td align="center" rowspan="1" colspan="1">55 (14.3%)</td><td align="center" rowspan="1" colspan="1">0.84</td><td align="center" rowspan="1" colspan="1">0.45&#x02013;1.57</td></tr><tr><td align="left" rowspan="1" colspan="1">Adenosquamous</td><td align="center" rowspan="1" colspan="1">13 (3.4%)</td><td align="center" rowspan="1" colspan="1">0.53</td><td align="center" rowspan="1" colspan="1">0.16&#x02013;1.78</td></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">28 (7.3%)</td><td align="center" rowspan="1" colspan="1">0.61</td><td align="center" rowspan="1" colspan="1">0.26&#x02013;1.43</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Race</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Caucasian</td><td align="center" rowspan="1" colspan="1">237 (61.6%)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">African-American</td><td align="center" rowspan="1" colspan="1">74 (19.2%)</td><td align="center" rowspan="1" colspan="1">1.22</td><td align="center" rowspan="1" colspan="1">0.72&#x02013;2.06</td></tr><tr><td align="left" rowspan="1" colspan="1">Other</td><td align="center" rowspan="1" colspan="1">74 (19.2%)</td><td align="center" rowspan="1" colspan="1">1.28</td><td align="center" rowspan="1" colspan="1">0.75&#x02013;2.18</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Residence</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Big Metropolitan area</td><td align="center" rowspan="1" colspan="1">235 (61.0%)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Metropolitan area</td><td align="center" rowspan="1" colspan="1">94 (24.4%)</td><td align="center" rowspan="1" colspan="1">1.48</td><td align="center" rowspan="1" colspan="1">0.89&#x02013;2.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Urban, less urban, rural</td><td align="center" rowspan="1" colspan="1">56 (14.5%)</td><td align="center" rowspan="1" colspan="1">2.63</td><td align="center" rowspan="1" colspan="1">1.41&#x02013;4.91</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Socioeconomic status, median income</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;30,700</td><td align="center" rowspan="1" colspan="1">94 (24.4%)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">30,701&#x02013;39,425</td><td align="center" rowspan="1" colspan="1">93 (24.2%)</td><td align="center" rowspan="1" colspan="1">0.77</td><td align="center" rowspan="1" colspan="1">0.47&#x02013;1.28</td></tr><tr><td align="left" rowspan="1" colspan="1">39,426&#x02013;53,707</td><td align="center" rowspan="1" colspan="1">102 (26.5%)</td><td align="center" rowspan="1" colspan="1">0.72</td><td align="center" rowspan="1" colspan="1">0.43&#x02013;1.20</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;53,708</td><td align="center" rowspan="1" colspan="1">96 (24.9%)</td><td align="center" rowspan="1" colspan="1">1.18</td><td align="center" rowspan="1" colspan="1">0.70&#x02013;1.98</td></tr><tr><td align="center" colspan="4" rowspan="1"><hr/></td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidity index, Charlson</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">274 (71.2%)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">63 (16.4%)</td><td align="center" rowspan="1" colspan="1">1.09</td><td align="center" rowspan="1" colspan="1">0.61&#x02013;1.94</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">28 (7.3%)</td><td align="center" rowspan="1" colspan="1">0.72</td><td align="center" rowspan="1" colspan="1">0.31&#x02013;1.65</td></tr><tr><td align="left" rowspan="1" colspan="1">3+</td><td align="center" rowspan="1" colspan="1">20 (5.2%)</td><td align="center" rowspan="1" colspan="1">0.8</td><td align="center" rowspan="1" colspan="1">0.31&#x02013;2.10</td></tr></tbody></table><table-wrap-foot><fn><p>*Adjusted for variables listed in the tables.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>